A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients. An anti-cancer compound developed at the University of Michigan has shown “profound” activity in mouse models against two subtypes of leukemia — representing up to 40% of patients — a U-M research team reports in the Journal of...
